---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-001556"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:06:23.732229+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma Phase 4 PIFR-2 study of YUPELRI fails to meet primary endpoint vs Spiriva HandiHaler in severe COPD

## Summary
- PIFR-2 study did not show statistically significant difference on primary endpoint (change in trough FEV1 at Day 85) for YUPELRI vs Spiriva HandiHaler.
- Both arms demonstrated similar lung function improvement; YUPELRI safety and tolerability consistent with prior studies.
- Study enrolled adults with severe to very severe COPD (FEV1 <50% predicted) and suboptimal PIFR (<55 L/min).
- CEO Rick E Winningham noted growth opportunities ahead for YUPELRI, an important COPD maintenance option.

## SEC filing metadata
- accession: 0001104659-24-001556
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465924001556/0001104659-24-001556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465924001556/tm242154d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-001556
- JSON: https://secwatch.observer/filing/0001104659-24-001556.json
- Plain text: https://secwatch.observer/filing/0001104659-24-001556.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.